2 active not recruiting, 1 completed, 1 recruiting, 1 terminated. 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Colitis, Microscopic: new trials by email Literature Review of Colitis, Microscopic trials Research Report on Colitis, Microscopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission SAR444336, Placebo - Microscopic Colitis | Phase 2 | Active not recruiting | Sanofi | 60 | 2025-10-14 | 2026-11-12 |
| Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis Budesonide MMX®, Budesonide controlled ileal release (CR) capsules - Microscopic Colitis | Phase 2 | Active not recruiting | University of Calgary | 80 | 2024-03-21 | 2026-10-21 |
| Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis Rifaximin 550mg - Microscopic Colitis | Phase 2 | Recruiting | Eugene F Yen, MD | 10 | 2018-06-29 | 2021-04-15 |
| Trial of Mesalamine for the Treatment of Active Microscopic Colitis Mesalamine - Microscopic Colitis, Diarrhea | Phase 2 / Phase 3 | Completed | Mayo Clinic | 70 | 2007-02-01 | 2011-05-24 |
| Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis Placebo, Budesonide - Lymphocytic Colitis, Diarrhea | Phase 2 / Phase 3 | Terminated | Mayo Clinic | 16 | 2003-06-01 | 2021-11-02 |
Diarrhea (2) · Colitis, Lymphocytic (1)
Colitis (5) · Colonic Diseases (5) · Digestive System Diseases (5) · Gastroenteritis (5) · Gastrointestinal Diseases (5) · Intestinal Diseases (5) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Signs and Symptoms, Digestive (2)
Budesonide (2) · Capsules (1) · Mesalamine (1) · Rifaximin (1)
Mayo Clinic (2) · Eugene F Yen, MD (1) · Sanofi (1) · University of Calgary (1)
United States (3) · Belgium (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Poland (1) · Sweden (1) · United Kingdom (1)
Christopher Ma, MD MPH (1) · Darrell S. Pardi, M.D. (1) · Eugene Yen, MD (1)
UL1RR024150 (1)